Latest news with #ZacksRank
Yahoo
19 hours ago
- Business
- Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -229.41%. A quarter ago, it was expected that this developer of cell therapies would post a loss of $0.51 per share when it actually produced a loss of $0.67, delivering a surprise of -31.37%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Plus , which belongs to the Zacks Medical - Drugs industry, posted revenues of $1.06 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 42.76%. This compares to year-ago revenues of $1.68 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Plus shares have lost about 75.1% since the beginning of the year versus the S&P 500's gain of 0.5%. While Plus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Plus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.17 on $1.9 million in revenues for the coming quarter and -$0.67 on $8.23 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, IGC Pharma, Inc. (IGC), has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.02 per share in its upcoming report, which represents a year-over-year change of +50%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. IGC Pharma, Inc.'s revenues are expected to be $0.31 million, up 6.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Plus Therapeutics, Inc. (PSTV) : Free Stock Analysis Report IGC Pharma, Inc. (IGC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
19 hours ago
- Business
- Yahoo
Why AudioEye (AEYE) Dipped More Than Broader Market Today
AudioEye (AEYE) closed at $12.22 in the latest trading session, marking a -0.81% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.01%. Elsewhere, the Dow saw an upswing of 0.13%, while the tech-heavy Nasdaq depreciated by 0.32%. Shares of the company witnessed a gain of 11.19% over the previous month, beating the performance of the Computer and Technology sector with its gain of 10.75% and the S&P 500's gain of 6.43%. The investment community will be paying close attention to the earnings performance of AudioEye in its upcoming release. The company's earnings per share (EPS) are projected to be $0.16, reflecting a 33.33% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $9.94 million, showing a 17.31% escalation compared to the year-ago quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.71 per share and revenue of $41.51 million, indicating changes of +29.09% and +17.91%, respectively, compared to the previous year. It is also important to note the recent changes to analyst estimates for AudioEye. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 6.67% higher within the past month. AudioEye presently features a Zacks Rank of #2 (Buy). From a valuation perspective, AudioEye is currently exchanging hands at a Forward P/E ratio of 17.48. This represents a discount compared to its industry's average Forward P/E of 28.91. Investors should also note that AEYE has a PEG ratio of 0.7 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Internet - Software was holding an average PEG ratio of 2.03 at yesterday's closing price. The Internet - Software industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 53, putting it in the top 22% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Audioeye, Inc. (AEYE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Business
- Yahoo
GameStop (GME) Advances While Market Declines: Some Information for Investors
In the latest trading session, GameStop (GME) closed at $29.80, marking a +0.78% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a gain of 0.13%, and the technology-centric Nasdaq decreased by 0.32%. Coming into today, shares of the video game retailer had gained 7.8% in the past month. In that same time, the Consumer Discretionary sector gained 7.31%, while the S&P 500 gained 6.43%. Investors will be eagerly watching for the performance of GameStop in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on June 10, 2025. It is anticipated that the company will report an EPS of $0.08, marking a 166.67% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $750 million, indicating a 14.95% downward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $0.47 per share and a revenue of $3.4 billion, signifying shifts of +42.42% and -11.06%, respectively, from the last year. Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for GameStop. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, GameStop is carrying a Zacks Rank of #3 (Hold). Digging into valuation, GameStop currently has a Forward P/E ratio of 62.92. Its industry sports an average Forward P/E of 19.17, so one might conclude that GameStop is trading at a premium comparatively. The Gaming industry is part of the Consumer Discretionary sector. This group has a Zacks Industry Rank of 90, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GameStop Corp. (GME) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
19 hours ago
- Business
- Yahoo
Hasbro (HAS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The most recent trading session ended with Hasbro (HAS) standing at $66.71, reflecting a -0.13% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.01%. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq lost 0.32%. Shares of the toy maker witnessed a gain of 10.03% over the previous month, beating the performance of the Consumer Discretionary sector with its gain of 7.31% and the S&P 500's gain of 6.43%. Analysts and investors alike will be keeping a close eye on the performance of Hasbro in its upcoming earnings disclosure. The company's upcoming EPS is projected at $0.77, signifying a 36.89% drop compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $874.39 million, down 12.15% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.22 per share and a revenue of $4.19 billion, signifying shifts of +5.24% and +1.41%, respectively, from the last year. Investors should also pay attention to any latest changes in analyst estimates for Hasbro. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.44% higher. Hasbro is currently a Zacks Rank #3 (Hold). Looking at valuation, Hasbro is presently trading at a Forward P/E ratio of 15.81. Its industry sports an average Forward P/E of 11.96, so one might conclude that Hasbro is trading at a premium comparatively. We can additionally observe that HAS currently boasts a PEG ratio of 1.84. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As the market closed yesterday, the Toys - Games - Hobbies industry was having an average PEG ratio of 1.92. The Toys - Games - Hobbies industry is part of the Consumer Discretionary sector. This industry, currently bearing a Zacks Industry Rank of 30, finds itself in the top 13% echelons of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow HAS in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hasbro, Inc. (HAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Business
- Yahoo
Cresco Labs Inc. (CRLBF) Reports Q1 Loss, Tops Revenue Estimates
Cresco Labs Inc. (CRLBF) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.01, delivering no surprise. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Cresco Labs Inc. , which belongs to the Zacks Medical - Products industry, posted revenues of $165.76 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.84%. This compares to year-ago revenues of $184.29 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Cresco Labs Inc. Shares have lost about 25.8% since the beginning of the year versus the S&P 500's gain of 0.5%. While Cresco Labs Inc. Has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Cresco Labs Inc. Mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.03 on $170.14 million in revenues for the coming quarter and -$0.09 on $692.17 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Ayr Wellness Inc. (AYRWF), another stock in the same industry, has yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -14.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Ayr Wellness Inc.'s revenues are expected to be $108.73 million, down 7.9% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cresco Labs Inc. (CRLBF) : Free Stock Analysis Report Ayr Wellness Inc. (AYRWF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
